Multifactorial Regulation of E-Cadherin Expression: An Integrative Study

E-cadherin (E-cad) is an adhesion molecule associated with tumor invasion and metastasis. Its down-regulation is associated with poor prognosis for many epithelial tumor types. We have profiled E-cad in the NCI-60 cancer cell lines at the DNA, RNA, and protein levels using six different microarray platforms plus bisulfite sequencing. Here we consider the effects on E-cad expression of eight potential regulatory factors: E-cad promoter DNA methylation, the transcript levels of six transcriptional repressors (SNAI1, SNAI2, TCF3, TCF8, TWIST1, and ZFHX1B), and E-cad DNA copy number. Combined bioinformatic and pharmacological analyses indicate the following ranking of influence on E-cad expression: (1) E-cad promoter methylation appears predominant, is strongly correlated with E-cad expression, and shows a 20% to 30% threshold above which E-cad expression is silenced; (2) TCF8 expression levels correlate with (−0.62) and predict (P < 0.00001) E-cad expression; (3) SNAI2 and ZFHX1B expression levels correlate positively with each other (+0.83) and also correlate with (−0.32 and −0.30, respectively) and predict (P = 0.03 and 0.01, respectively) E-cad expression; (4) TWIST1 correlates with (−0.34) but does not predict E-cad expression; and (5) SNAI1 expression, TCF3 expression, and E-cad DNA copy number do not correlate with or predict E-cad expression. Predictions of E-cad regulation based on the above factors were tested and verified by demethylation studies using 5-aza-2′-deoxycytidine treatment; siRNA knock-down of TCF8, SNAI2, or ZFHX1B expression; and combined treatment with 5-aza-2′-deoxycytidine and TCF8 siRNA. Finally, levels of cellular E-cad expression are associated with levels of cell-cell adhesion and response to drug treatment. Mol Cancer Ther; 9(1); 1–16

[1]  Sudhir Varma,et al.  DNA fingerprinting of the NCI-60 cell line panel , 2009, Molecular Cancer Therapeutics.

[2]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[3]  Sun-Mi Park,et al.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.

[4]  John N Weinstein,et al.  MicroRNA expression profiles for the NCI-60 cancer cell panel , 2007, Molecular Cancer Therapeutics.

[5]  Jae K. Lee,et al.  Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study , 2007, Molecular Cancer Therapeutics.

[6]  A. Feinberg,et al.  Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells , 2007, Molecular Cancer Therapeutics.

[7]  Gabriel S. Eichler,et al.  Asparagine synthetase as a causal, predictive biomarker for l-asparaginase activity in ovarian cancer cells , 2006, Molecular Cancer Therapeutics.

[8]  John N. Weinstein,et al.  Spotlight on molecular profiling: “Integromic” analysis of the NCI-60 cancer cell lines , 2006, Molecular Cancer Therapeutics.

[9]  Richard Lugg,et al.  Mutation analysis of 24 known cancer genes in the NCI-60 cell line set , 2006, Molecular Cancer Therapeutics.

[10]  William C Reinhold,et al.  Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel , 2006, Molecular Cancer Therapeutics.

[11]  Robert Brown,et al.  Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. , 2005, Carcinogenesis.

[12]  John N Weinstein,et al.  Analysis of ATP-Binding Cassette Transporter Expression in Drug-Selected Cell Lines by a Microarray Dedicated to Multidrug Resistances⃞ , 2004, Molecular Pharmacology.

[13]  Yuhei Yamamoto,et al.  Epigenetic silencing of E- and P-cadherin gene expression in human melanoma cell lines. , 2004, International journal of oncology.

[14]  M. Herlyn,et al.  Reversal of melanocytic malignancy by keratinocytes is an E-cadherin-mediated process overriding beta-catenin signaling. , 2004, Experimental cell research.

[15]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[16]  J. Weinstein,et al.  Karyotypic complexity of the NCI-60 drug-screening panel. , 2003, Cancer research.

[17]  William C Reinhold,et al.  Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Robert M. Gemmill,et al.  WNT7a induces E-cadherin in lung cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Anne Bergmann,et al.  Methylation-sensitive binding of transcription factor YY1 to an insulator sequence within the paternally expressed imprinted gene, Peg3. , 2003, Human molecular genetics.

[20]  M. Fraga,et al.  The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors , 2003, Journal of Cell Science.

[21]  G. Ellison,et al.  Further evidence to support the melanocytic origin of MDA-MB-435 , 2002, Molecular pathology : MP.

[22]  J. Weinstein.  'Omic' and hypothesis-driven research in the molecular pharmacology of cancer. , 2002, Current opinion in pharmacology.

[23]  P. Carroll,et al.  CpG hypermethylation of promoter region and inactivation of E‐cadherin gene in human bladder cancer , 2002, Molecular carcinogenesis.

[24]  E. Fearon,et al.  The SLUG zinc-finger protein represses E-cadherin in breast cancer. , 2002, Cancer research.

[25]  J. Mesirov,et al.  Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  R. Dahiya,et al.  CpG methylation of promoter region inactivates E‐cadherin gene in renal cell carcinoma , 2001, Molecular carcinogenesis.

[27]  P. Carroll,et al.  Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer. , 2001, The Journal of urology.

[28]  M. Nieto,et al.  A New Role for E12/E47 in the Repression ofE-cadherin Expression and Epithelial-Mesenchymal Transitions* , 2001, The Journal of Biological Chemistry.

[29]  G. Berx,et al.  The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. , 2001, Molecular cell.

[30]  R. Makino,et al.  Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  R. Eeles,et al.  Molecular markers for predicting prostate cancer stage and survival , 2000, BJU international.

[32]  J. Herman,et al.  Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. , 2000, Cancer research.

[33]  Shirley M. Tilghman,et al.  CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus , 2000, Nature.

[34]  M. Herlyn,et al.  Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. , 2000, Journal of cell science.

[35]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[36]  Christian A. Rees,et al.  Systematic variation in gene expression patterns in human cancer cell lines , 2000, Nature Genetics.

[37]  A. G. Herreros,et al.  The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells , 2000, Nature Cell Biology.

[38]  Shiva M. Singh,et al.  Site-specific DNA methylation in the neurofibromatosis (NF1) promoter interferes with binding of CREB and SP1 transcription factors , 1999, Oncogene.

[39]  D. Evans,et al.  Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. , 1999, Human molecular genetics.

[40]  G. Christofori,et al.  The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. , 1999, Trends in biochemical sciences.

[41]  D Pinkel,et al.  Mechanisms of inactivation of E-cadherin in breast cancer cell lines. , 1998, Cancer research.

[42]  W. Isaacs,et al.  The cadherin cell-cell adhesion pathway in prostate cancer progression. , 1997, British journal of urology.

[43]  C. Bierkamp,et al.  Cadherins and catenins in development. , 1996, Current opinion in cell biology.

[44]  J. Kononen,et al.  Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. , 1996, American journal of clinical pathology.

[45]  M. Vijver,et al.  E‐cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. , 1995, The EMBO journal.

[46]  S. Hirohashi,et al.  Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Ikura,et al.  Solution structure of the epithelial cadherin domain responsible for selective cell adhesion , 1995, Science.

[48]  M. Boyd,et al.  Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. , 1992, Anticancer research.

[49]  O. Ogawa,et al.  Multipoint methylation and expression analysis of tumor suppressor genes in human renal cancer cells. , 2003, Urology.